人免疫球蛋白静脉注射辅助治疗小儿重症肺炎疗效观察

The rapeutic effectiveness observation for the adjuvant treatment of infant severe pneumonia by intravenous injection of human immunoglobulin

目的探讨人免疫球蛋白静脉注射辅助治疗小儿重症肺炎的疗效。方法将78例重症肺炎患儿按家属自愿原则随机分为对照和治疗两组,两组均进行综合治疗,治疗组在综合治疗的基础上加用人免疫球蛋白。比较两组的症状消失时间、X线胸片显示吸收好转时间及住院时间;比较两组的疗效。结果两组症状、体征消失时间、X线胸片示炎症吸收好转及住院时间比较有显著性差异(P<0.05);两组疗效比较有显著性差异(P<0.05);治疗组患儿无明显不良反应。结论人免疫球蛋白辅助治疗小儿重症肺炎安全有效,值得临床推广。

[ Objective ] To investigate the efficacy of intravenous injection of human immunoglobulin in the adjuvant treatment of infant severe pneumonia. [ Methods ] Divide 78 cases of infant severe pneumonia, with the voluntariness from their families, into the control group and the treatment group, and give comprehensive treatment to the both groups. In addition, the infants in the treatment group were also given human immunoglobulin. Compare the two groups in terms of symptom disappearing time, absorption and recovery time shown by X-ray chest radiography and the hospitalization period. [ Resluts ] There was significant difference （P〈0.05） in the comparison between the two groups in terms of symptom disappearing time, absorption and recovery time shown by X-ray chest radiography and the hospitalization period, as well as the therapeutic effectiveness. The treatment group had no significant adverse reaction. [ Conclusion ] The intravenous injection of human immunoglobulin in the adjuvant treatment of infant severe pneumonia is safe and effective, worthy of clinical promotion.